Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 76 articles:
HTML format
Text format



Single Articles


    September 2017
  1. ARGUELLES-ARIAS F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, et al
    Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Eur J Gastroenterol Hepatol. 2017 Sep 8. doi: 10.1097/MEG.0000000000000953.
    PubMed     Text format     Abstract available


  2. TIMMER A, Stark R, Peplies J, Classen M, et al
    Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease: a survey-based analysis on 1280 patients aged 10-25 years focusing on differences by age of onset.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000956.
    PubMed     Text format     Abstract available


    August 2017
  3. COUCOUTSI C, Emmanouil G, Goulielmos G, Sfakianaki O, et al
    Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000947.
    PubMed     Text format     Abstract available


    June 2017
  4. HOEKMAN DR, Zeevenhooven J, D'Haens GR, Benninga MA, et al
    The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Eur J Gastroenterol Hepatol. 2017 Jun 21. doi: 10.1097/MEG.0000000000000921.
    PubMed     Text format     Abstract available


    May 2017
  5. ORTIZO R, Lee SY, Nguyen ET, Jamal MM, et al
    Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies.
    Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000915.
    PubMed     Text format     Abstract available


  6. RINAWI F, Assa A, Eliakim R, Mozer Glassberg Y, et al
    Predictors of pouchitis after ileal pouch-anal anastomosis in pediatric-onset ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000914.
    PubMed     Text format     Abstract available


  7. BAHLER C, Schoepfer AM, Vavricka SR, Brungger B, et al
    Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000891.
    PubMed     Text format     Abstract available


  8. WARDLE RA, Wardle AJ, Charadva C, Ghosh S, et al
    Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000899.
    PubMed     Text format     Abstract available


  9. HERZOG D, Fournier N, Buehr P, Rueger V, et al
    Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000896.
    PubMed     Text format     Abstract available


  10. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
    Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2017;29:577-586.
    PubMed     Text format     Abstract available


  11. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Text format     Abstract available


    April 2017
  12. DRAGASEVIC S, Stankovic B, Milosavljevic T, Sokic-Milutinovic A, et al
    Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2017 Apr 27. doi: 10.1097/MEG.0000000000000877.
    PubMed     Text format     Abstract available


    March 2017
  13. VAN DEEN WK, Spiro A, Burak Ozbay A, Skup M, et al
    The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study.
    Eur J Gastroenterol Hepatol. 2017;29:331-337.
    PubMed     Text format     Abstract available


    February 2017
  14. YERUSHALMY-FELER A, Ron Y, Barnea E, Nachum A, et al
    Adolescent transition clinic in inflammatory bowel disease: quantitative assessment of self-efficacy skills.
    Eur J Gastroenterol Hepatol. 2017 Feb 22. doi: 10.1097/MEG.0000000000000864.
    PubMed     Text format     Abstract available


  15. TRIANTAFYLLOU K, Gkolfakis P, Viazis N, Tsibouris P, et al
    A 13-year time trend analysis of 3724 small bowel video capsule endoscopies and a forecast model during the financial crisis in Greece.
    Eur J Gastroenterol Hepatol. 2017;29:185-191.
    PubMed     Text format     Abstract available


  16. DURICOVA D, Fumery M, Annese V, Lakatos PL, et al
    The natural history of Crohn's disease in children: a review of population-based studies.
    Eur J Gastroenterol Hepatol. 2017;29:125-134.
    PubMed     Text format     Abstract available


    January 2017
  17. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000838.
    PubMed     Text format     Abstract available


  18. COENEN S, Weyts E, Vermeire S, Ferrante M, et al
    Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care.
    Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000839.
    PubMed     Text format     Abstract available


  19. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
    Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2017 Jan 4. doi: 10.1097/MEG.0000000000000826.
    PubMed     Text format     Abstract available


    December 2016
  20. VAN ERP SJ, Verheul MK, Levarht EW, van der Reijden JJ, et al
    Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  21. ROSSI RE, Whyand T, Murray CD, Hamilton MI, et al
    The role of dietary supplements in inflammatory bowel disease: a systematic review.
    Eur J Gastroenterol Hepatol. 2016;28:1357-1364.
    PubMed     Text format     Abstract available


    November 2016
  22. VAN GENNEP S, Sahami S, Buskens CJ, van den Brink GR, et al
    Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  23. ZEITZ J, Bissig M, Barthel C, Biedermann L, et al
    Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  24. FALT P, Smajstrla V, Fojtik P, Hill M, et al
    Carbon dioxide insufflation during colonoscopy in inflammatory bowel disease patients: a double-blind, randomized, single-center trial.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  25. GOYAL H, Singla U, Gupta U, May E, et al
    Role of cannabis in digestive disorders.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  26. TAKS M, Pijls PA, Derijks LJ, Ten Broeke R, et al
    The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  27. JOHNSEN KM, Goll R, Hansen V, Olsen T, et al
    Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  28. FRAGA M, Fournier N, Safroneeva E, Pittet V, et al
    Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  29. WAUTERS L, Billiet T, Papamichael K, Ballet V, et al
    Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  30. ARDESIA M, Costantino G, Fries W
    Lower response to the hepatitis B vaccine in future inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016;28:1101-2.
    PubMed     Text format    


    August 2016
  31. VEERAPPAN SG, Healy M, Walsh B, O'Morain CA, et al
    A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  32. CAMPOS S, Portela F, Sousa P, Sofia C, et al
    Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  33. BONTA J, Zeitz J, Frei P, Biedermann L, et al
    Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  34. OXELMARK L, Lindberg A, Lofberg R, Sternby B, et al
    Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  35. SOARES JB, Pereira R, Costa JM, Arroja B, et al
    The Inflammatory Bowel Disease-Disability Index: validation of the Portuguese version according to the COSMIN checklist.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  36. NIV Y
    Mucin gene expression in the intestine of ulcerative colitis patients: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  37. DE BOER AG, Bennebroek Evertsz' F, Stokkers PC, Bockting CL, et al
    Employment status, difficulties at work and quality of life in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  38. CARPIO D, Lopez-Sanroman A, Calvet X, Romero C, et al
    Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  39. DE GROOF EJ, Rossen NG, van Rhijn BD, Karregat EP, et al
    Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  40. DUJARDIN RW, Meijer B, de Boer NK, D'Haens GR, et al
    Usefulness of mean corpuscular volume as a surrogate marker for monitoring thiopurine treatment in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  41. ZHENG HH, Jiang XL
    Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.
    Eur J Gastroenterol Hepatol. 2016;28:383-90.
    PubMed     Text format     Abstract available


  42. LEE YJ, Hwang EH, Park JH, Shin JH, et al
    NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2016;28:475-8.
    PubMed     Text format     Abstract available


    March 2016
  43. PARISI I, O'Beirne J, Rossi RE, Tsochatzis E, et al
    Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  44. TERZOUDIS S, Malliaraki N, Damilakis J, Dimitriadou DA, et al
    Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  45. MADIRRALA V, Rooney P, Heath RM, Campbell F, et al
    Short article: Successful faecal coliform sensitivity-based oral ertapenem therapy for chronic antibiotic-refractory pouchitis: a case series.
    Eur J Gastroenterol Hepatol. 2016;28:277-80.
    PubMed     Text format     Abstract available


  46. BOND A, Asher R, Jackson R, Sager K, et al
    Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Eur J Gastroenterol Hepatol. 2016;28:271-6.
    PubMed     Text format     Abstract available


    February 2016
  47. BODELIER AG, Pierik MJ, Lenaerts K, de Boer E, et al
    Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  48. WASZCZUK E, Waszczuk KM, Mulak A, Paradowski L, et al
    Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  49. KUCHARSKI M, Karczewski J, Mankowska-Wierzbicka D, Karmelita-Katulska K, et al
    Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  50. FRANCESCHET I, Cazzagon N, Del Ross T, D'Inca R, et al
    Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  51. GUT G, Ben-Tov A, Lahad A, Soferman R, et al
    Pulmonary functions in children with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  52. KUIN S, Stolte SB, van den Brink GR, Ponsioen CY, et al
    Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2016;28:222-5.
    PubMed     Text format     Abstract available


    January 2016
  53. THORNE K, Alrubaiy L, Akbari A, Samuel DG, et al
    Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  54. COENEN S, Weyts E, Ballet V, Noman M, et al
    Identifying predictors of low adherence in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  55. WAHID AM, Devarajan K, Ross A, Zilbauer M, et al
    Paediatric gastrointestinal endoscopy: a qualitative study.
    Eur J Gastroenterol Hepatol. 2016;28:25-9.
    PubMed     Text format     Abstract available


    December 2015
  56. WOJTOWICZ AA, Plevinsky JM, Poulopoulos N, Schurman JV, et al
    Examining predictors of healthcare utilization in youth with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  57. ROSSI RE, Conte D, Massironi S
    Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  58. HUSSEY M, Mc Garrigle R, Kennedy U, Holleran G, et al
    Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  59. DIBLEY L, Norton C, Cotterill N, Bassett P, et al
    Development and initial validation of a disease-specific bowel continence questionnaire for inflammatory bowel disease patients: the ICIQ-IBD.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  60. LEE SY, Jamal MM, Nguyen ET, Bechtold ML, et al
    Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  61. BOLLEN L, Vande Casteele N, Ballet V, van Assche G, et al
    Thromboembolism as an important complication of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  62. SOARES JB, Nogueira MC, Fernandes D, Goncalves BM, et al
    Validation of the Portuguese version of a questionnaire to measure Quality of Care Through the Eyes of Patients with Inflammatory Bowel Disease (QUOTE-IBD).
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  63. VOLONAKI E, Mutalib M, Kiparissi F, Shah N, et al
    Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  64. SCAIOLI E, Scagliarini M, Cardamone C, Liverani E, et al
    Clinical application of faecal calprotectin in ulcerative colitis patients.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  65. BELLE A, Baumann C, Bigard MA, Zallot C, et al
    Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2015;27:877-81.
    PubMed     Text format     Abstract available


    July 2015
  66. FRELING E, Peyrin-Biroulet L, Poreaux C, Morali A, et al
    IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    June 2015
  67. CARPIO D, Barreiro-de Acosta M, Echarri A, Pereira S, et al
    Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: a cross-sectional study.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  68. SOARES JB, Marinho AS, Fernandes D, Moreira Goncalves B, et al
    Assessing overall patient satisfaction in inflammatory bowel disease using structural equation modeling.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    April 2015
  69. VIAZIS N, Koukouratos T, Anastasiou J, Giakoumis M, et al
    Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Eur J Gastroenterol Hepatol. 2015;27:436-41.
    PubMed     Text format     Abstract available


  70. ECHARRI A, Ollero V, Barreiro-de Acosta M, Fernandez-Villaverde A, et al
    Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice.
    Eur J Gastroenterol Hepatol. 2015;27:430-5.
    PubMed     Text format     Abstract available


    March 2015
  71. NGUYEN DL, Nguyen ET, Bechtold ML
    Outcomes of initial medical compared with surgical strategies in the management of intra-abdominal abscesses in patients with Crohn's disease: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2015;27:235-41.
    PubMed     Text format     Abstract available


    February 2015
  72. PELLINO G, Sciaudone G, Selvaggi F, Riegler G, et al
    Delayed diagnosis is influenced by the clinical pattern of Crohn's disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in Southern Italy.
    Eur J Gastroenterol Hepatol. 2015;27:175-81.
    PubMed     Text format     Abstract available


    January 2015
  73. AGGARWAL D, Limdi JK
    Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2015;27:13-9.
    PubMed     Text format     Abstract available


    December 2014
  74. PICHE T, Pishvaie D, Tirouvaziam D, Filippi J, et al
    Osteopathy decreases the severity of IBS-like symptoms associated with Crohn's disease in patients in remission.
    Eur J Gastroenterol Hepatol. 2014;26:1392-8.
    PubMed     Text format     Abstract available


    October 2014
  75. NGUYEN DL, Solaimani P, Nguyen ET, Jamal MM, et al
    Antitumor necrosis factor alpha is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn's disease: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2014;26:1152-9.
    PubMed     Text format     Abstract available


  76. MACONI G, Lombardini M, Furfaro F, Bezzio C, et al
    Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment.
    Eur J Gastroenterol Hepatol. 2014;26:1146-51.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: